Presentation is loading. Please wait.

Presentation is loading. Please wait.

A CC perspective on the three Cs: Collaboration, Communication and Capacity building Anne Kelso Director WHO Collaborating Centre for Reference and Research.

Published bySharlene Ford Modified over 9 years ago

Similar presentations

Presentation on theme: "A CC perspective on the three Cs: Collaboration, Communication and Capacity building Anne Kelso Director WHO Collaborating Centre for Reference and Research."— Presentation transcript:

1 A CC perspective on the three Cs: Collaboration, Communication and Capacity building Anne Kelso Director WHO Collaborating Centre for Reference and Research on Influenza 5 th WHO National Influenza Centres Meeting, Vientiane, June 2011

2 The three Cs Collaboration Communication Capacity building (Patrick Reading) virological surveillance and isolation of vaccine viruses research

3 Collaboration in virological surveillance and isolation of vaccine viruses

4 Countries that submitted samples to WHO CCs in 2010 US CDC (Atlanta) NIMR (London) VIDRL (Melbourne) NIID (Tokyo) CCDC (Beijing)

5 Collaboration in virological surveillance and isolation of vaccine viruses (1) What CCs need from NICs: What NICs need from CCs:

6 Collaboration in virological surveillance and isolation of vaccine viruses (1) What CCs need from NICs: What NICs need from CCs: Urgent submission of any novel or unsubtypable viruses Submission of representative recent circulating viruses to provide a global picture and contribute to vaccine strain selection by WHO Any relevant clinical or epidemiological information Submission of some clinical specimens for isolation of vaccine candidates

7 Collaboration in virological surveillance and isolation of vaccine viruses (1) What CCs need from NICs: What NICs need from CCs: Urgent submission of any novel or unsubtypable viruses Submission of representative recent circulating viruses to provide a global picture and contribute to vaccine strain selection by WHO Any relevant clinical or epidemiological information Submission of some clinical specimens for isolation of vaccine candidates Urgent identification of novel or unsubtypable viruses Rapid reporting of results for circulating viruses (eg, strains, antiviral drug resistance) Availability of vaccines matched to circulating viruses in your country Anything else?

8 Collaboration in virological surveillance and isolation of vaccine viruses (2) Novel and unsubtypable viruses: Contact us first: - email, telephone, fax, smoke signals… (not facebook or twitter!) We can discuss technical issues, compare primer sequences, etc We can prepare to receive the viruses Send us the viruses as soon as possible Urgent samples go to the front of the queue! We will contact you about the results as soon as we have them.

9 Timing of virus submission to CCs: strain selection WHO Consultation for Southern Hemisphere WHO Consultation for Northern Hemisphere

10 Collaboration in virological surveillance and isolation of vaccine viruses (3) Representative recent circulating viruses: Send some viruses as often as you can They are most useful if they are recent Send some early in your season as well as later, so we have results in time for WHO Consultation Inter-season viruses are also useful Send us clinical or epidemiological information if you have it. We are testing a new electronic submission form – easier for NICs?

11 Collaboration in virological surveillance and isolation of vaccine viruses (4) Representative recent circulating viruses: We will report HI and antiviral resistance results as soon as we have them Reporting time depends on…. shipping time delays in customs if we don’t know samples are coming whether virus needs to be isolated how easily it grows in MDCK cells how many other viruses arrive at same time how urgent Please tell us if you need more information or explanation of results in reports.

12 * Samples received in the year following sample date Samples submitted to WHO CC at VIDRL, 2007 – 2010 4044 samples 47 laboratories 20 countries

13 Analysis of submitted viruses at WHO CC Clinical specimen Antigenic analysis (HI, MN) HA and NA sequence Antiviral drug sensitivity (phenotypic, genotypic assays) Other testing (eg, human serology) Confirm HI & sequence Raise ferret antiserum Egg isolate Vaccine candidates Isolate MDCK isolate MDCK cells Eggs PCR Sequence

14 What else do we do with submitted viruses? Supply HI data to Cambridge University for antigenic cartography Raise post-infection ferret antisera against interesting viruses Full genome sequencing; test for reassortment (pyrosequencing) Follow up viruses showing unusual neuraminidase inhibitor resistance Analyse reactivity of serum panels from vaccine trials (Australia, Japan, Europe, US) with recent reference strains Prepare reagent kits for provision to requesting laboratories Study pathogenicity, transmission and immunological responses in ferrets

15 The importance of egg-isolated viruses Regulators require that influenza vaccine viruses are isolated and passaged exclusively in hen’s eggs (or primary egg-derived cells). WHO Collaborating Centres obtain egg isolates as candidate vaccine strains for provision to vaccine manufacturers (after reasssortment of type A viruses). Viruses are adapted growth in eggs by amniotic passage then growth in the allantoic cavity.

16 Timing of virus submission to CCs: vaccine candidates WHO Consultation for Southern Hemisphere WHO Consultation for Northern Hemisphere

17 WHO recommendations for seasonal vaccines YearMonthA(H1N1)A(H3N2)B 2000FebruaryA/New Caledonia/20/99A/Moscow/10/99B/Beijing/184/93 SeptemberA/New Caledonia/20/99A/Moscow/10/99B/Sichuan/379/99 2001FebruaryA/New Caledonia/20/99A/Moscow/10/99B/Sichuan/379/99 SeptemberA/New Caledonia/20/99A/Moscow/10/99B/Sichuan/379/99 2002FebruaryA/New Caledonia/20/99A/Moscow/10/99B/Hong Kong/330/2001 SeptemberA/New Caledonia/20/99A/Moscow/10/99B/Hong Kong/330/2001 2003FebruaryA/New Caledonia/20/99A/Moscow/10/99B/Hong Kong/330/2001 SeptemberA/New Caledonia/20/99A/Fujian/411/2002B/Hong Kong/330/2001 2004FebruaryA/New Caledonia/20/99A/Fujian/411/2002B/Shanghai/361/2002 SeptemberA/New Caledonia/20/99A/Wellington/1/2004B/Shanghai/361/2002 2005FebruaryA/New Caledonia/20/99A/California/7/2004B/Shanghai/361/2002 SeptemberA/New Caledonia/20/99A/California/7/2004B/Malaysia/2506/2004 2006FebruaryA/New Caledonia/20/99A/Wisconsin/67/2005B/Malaysia/2506/2004 SeptemberA/New Caledonia/20/99A/Wisconsin/67/2005B/Malaysia/2506/2004 2007FebruaryA/Solomon Islands/3/2006A/Wisconsin/67/2005B/Malaysia/2506/2004 SeptemberA/Solomon Islands/3/2006A/Brisbane/10/2007B/Florida/4/2006 2008FebruaryA/Brisbane/59/2007A/Brisbane/10/2007B/Florida/4/2006 SeptemberA/Brisbane/59/2007A/Brisbane/10/2007B/Florida/4/2006 2009FebruaryA/Brisbane/59/2007A/Brisbane/10/2007B/Brisbane/60/2008 SeptemberA/California/7/2009 (pdm)A/Perth/16/2009B/Brisbane/60/2008 2010FebruaryA/California/7/2009A/Perth/16/2009B/Brisbane/60/2008 SH 2010 NH 2010-11 SH 2011 NH 2011-12 SeptemberA/California/7/2009A/Perth/16/2009B/Brisbane/60/2008 2011FebruaryA/California/7/2009A/Perth/16/2009B/Brisbane/60/2008

18 WHO recommended vaccine viruses from WPR YearMonthA(H1N1)A(H3N2)B 2000FebruaryA/New Caledonia/20/99B/Beijing/184/93 SeptemberA/New Caledonia/20/99B/Sichuan/379/99 2001FebruaryA/New Caledonia/20/99B/Sichuan/379/99 SeptemberA/New Caledonia/20/99B/Sichuan/379/99 2002FebruaryA/New Caledonia/20/99B/Hong Kong/330/2001 SeptemberA/New Caledonia/20/99B/Hong Kong/330/2001 2003FebruaryA/New Caledonia/20/99B/Hong Kong/330/2001 SeptemberA/New Caledonia/20/99A/Fujian/411/2002B/Hong Kong/330/2001 2004FebruaryA/New Caledonia/20/99A/Fujian/411/2002B/Shanghai/361/2002 SeptemberA/New Caledonia/20/99A/Wellington/1/2004B/Shanghai/361/2002 2005FebruaryA/New Caledonia/20/99B/Shanghai/361/2002 SeptemberA/New Caledonia/20/99B/Malaysia/2506/2004 2006FebruaryA/New Caledonia/20/99B/Malaysia/2506/2004 SeptemberA/New Caledonia/20/99B/Malaysia/2506/2004 2007FebruaryA/Solomon Islands/3/2006B/Malaysia/2506/2004 SeptemberA/Solomon Islands/3/2006A/Brisbane/10/2007 2008FebruaryA/Brisbane/59/2007A/Brisbane/10/2007 SeptemberA/Brisbane/59/2007A/Brisbane/10/2007 2009FebruaryA/Brisbane/59/2007A/Brisbane/10/2007B/Brisbane/60/2008 SeptemberA/Perth/16/2009B/Brisbane/60/2008 2010FebruaryA/Perth/16/2009B/Brisbane/60/2008 SH 2010 NH 2010-11 SH 2011 NH 2011-12 SeptemberA/Perth/16/2009B/Brisbane/60/2008 2011FebruaryA/Perth/16/2009B/Brisbane/60/2008

19 Collaboration in research

20 Collaboration in research: the goal…. Collaboration on projects of mutual interest where each party brings specific expertise and/or resources (viruses, data, techniques etc) For example: with authors from Australia, South Africa, Cambodia, Thailand, Taiwan, New Caledonia, Macao, Singapore, Malaysia, Philippines and New Zealand If we can help with your research, please let us know. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa Aeron C. Hurt, Joanne Ernest, Yi-Mo Deng, Pina Iannello, Terry G. Besselaar, Chris Birch, Philippe Buchy, Malinee Chittaganpitch, Shu-Chun Chiu, Dominic Dwyer, Aurélie Guigon, Bruce Harrower, Ip Peng Kei, Tuckweng Kok, Cui Lin, Ken McPhie, Apandi Mohd, Remigio Olveda, Tony Panayotou, William Rawlinson, Lesley Scott, David Smith, Holly D'Souza, Naomi Komadina, Robert Shaw, Anne Kelso and Ian G. Barr Antiviral Research 83(1): 90 – 93 (2009)

21 Communication

22 How can we help each other through communication? Good human relationships underpin all successful endeavours Share virological, technical and other information so we can help each other and do our own work more effectively Strengthen our collaborative networks. Meet Talk Email Report Browse

23 www.influenzacentre.org

24 The three Cs Collaboration Communication Capacity building (Patrick Reading) virological surveillance and isolation of vaccine viruses research

25 Acknowledgements WHO National Influenza Centres and other submitting laboratories WHO Collaborating Centres and others in GISRS Staff of the Melbourne WHO Collaborating Centre: The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. Chantal Baas, Ian Barr, Iwona Buettner, Natalie Caldwell, Louise Carolan, Michelle Chow, Yi-Mo Deng, Joelle Dharmakumara, Chris Durrant, Aeron Hurt, Pina Iannello, Naomi Komadina, Karen Laurie, Leah Leang, Tasoula Mastorakos, Katie O’Bryan, Heidi Peck, Patrick Reading, Rob Shaw, Helen Sjogren

Download ppt "A CC perspective on the three Cs: Collaboration, Communication and Capacity building Anne Kelso Director WHO Collaborating Centre for Reference and Research."

Similar presentations

Surveillance in a Pandemic: Situational Awareness

Surveillance in a Pandemic: Situational Awareness
Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.

Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.
Characterization of human influenza virus circulation in Cambodia 2006-2010 and impact for national public health policies. Ly Sovann, MD, DTMH, MCTM Philippe.

Characterization of human influenza virus circulation in Cambodia and impact for national public health policies. Ly Sovann, MD, DTMH, MCTM Philippe.
Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) 2009 - Dr Wenqing Zhang Regional.

Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) Dr Wenqing Zhang Regional.
12/2/20041 Modern Methods for Influenza Detection and Sub-typing Ronald Cheshier.

12/2/20041 Modern Methods for Influenza Detection and Sub-typing Ronald Cheshier.
CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance in Mainland of China Yuelong Shu Chinese National Influenza Center National Institute.

CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance in Mainland of China Yuelong Shu Chinese National Influenza Center National Institute.
Communicable Disease Surveillance & Response WHO-WPRO Pandemic (H1N1) 2009 situation and response in the Western Pacific Region Takeshi Kasai Communicable.

Communicable Disease Surveillance & Response WHO-WPRO Pandemic (H1N1) 2009 situation and response in the Western Pacific Region Takeshi Kasai Communicable.
World Health Organization, 15 June 2003

World Health Organization, 15 June 2003
Avian Influenza A(H5N1) and Risks to Human Health Technical Meeting on Highly Pathogenic Avian Influenza and Human H5N1 infection Rome 27 - 29 June 2007.

Avian Influenza A(H5N1) and Risks to Human Health Technical Meeting on Highly Pathogenic Avian Influenza and Human H5N1 infection Rome June 2007.
Influenza Vaccine Manufacturing Industry perspective for 2013-2014 influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.
Influenza Virus Vaccine 2013-2014 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
Influenza Vaccine Manufacturing Industry perspective for 2012-2013 influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.
Laboratory training course: Proper selection, handling and shipping of samples for diagnosis of influenza and other respiratory viruses.

Laboratory training course: Proper selection, handling and shipping of samples for diagnosis of influenza and other respiratory viruses.
Influenza Virus Vaccine 2011-2012 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.
DR. JULIE LOUISE GERBERDING DIRECTOR CENTERS FOR DISEASE CONTROL AND PREVENTION CURRENT STATUS OF AVIAN INFLUENZA AND PANDEMIC THREAT PRESENTATION TO IOM,

DR. JULIE LOUISE GERBERDING DIRECTOR CENTERS FOR DISEASE CONTROL AND PREVENTION CURRENT STATUS OF AVIAN INFLUENZA AND PANDEMIC THREAT PRESENTATION TO IOM,
What should be taken into consideration when establishing antiviral resistance surveillance? Aeron Hurt WHO Collaborating Centre for Reference and Research.

What should be taken into consideration when establishing antiviral resistance surveillance? Aeron Hurt WHO Collaborating Centre for Reference and Research.
A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.

A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.
Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.
Progress Report Global Pandemic Preparedness Beijing Conference 17-18 January 2006 Dr Margaret Chan Assistant Director-General Communicable Diseases Representative.

Progress Report Global Pandemic Preparedness Beijing Conference January 2006 Dr Margaret Chan Assistant Director-General Communicable Diseases Representative.

Similar presentations

Ads by Google